Repaglinide
Repaglinide is an oral antidiabetic medicine used to improve blood glucose control in adults with type 2 diabetes mellitus, particularly to manage increases in blood sugar after meals. It belongs to the meglitinide class and works by stimulating insulin release from pancreatic beta cells in response to rising blood glucose levels. It is available as oral tablets and is generally taken shortly before meals, with doses adjusted according to blood glucose response. Common side effects include hypoglycaemia, weight gain, headache, and gastrointestinal discomfort. Important precautions include an increased risk of low blood sugar when meals are skipped or combined with other glucose-lowering medicines, and potential drug interactions, particularly with gemfibrozil. Repaglinide should be used under medical supervision, with regular blood glucose monitoring and appropriate dose adjustment.
Repaglinide was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Repaglinide, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Repaglinide from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Repaglinide, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
